LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Test Reveals Existing Antibiotics Can Cure Superbugs

By LabMedica International staff writers
Posted on 02 May 2023
Print article
Image: A new AST has revealed that FDA-approved antibiotics can treat multidrug-resistant infections (Photo courtesy of Freepik)
Image: A new AST has revealed that FDA-approved antibiotics can treat multidrug-resistant infections (Photo courtesy of Freepik)

A new test has revealed that FDA-approved antibiotics, readily available at local pharmacies, can effectively combat superbugs. These antibiotics are not prescribed due to the gold-standard test indicating their inefficacy. This novel test could revolutionize the development, testing, and prescription of antibiotics, playing a crucial role in the battle against bacterial resistance by optimizing the use of existing antibiotics and bolstering the search for new ones.

The antibiotic study by a team of scientists at UC Santa Barbara (Santa Barbara, CA, USA) tackled a fundamental issue in the current healthcare approach to determining antibiotic resistance, which fails to consider the environmental conditions within the body that influence drug efficacy. By replicating these conditions, the new test pinpointed several effective antibiotics that standard testing had dismissed. When both the new and standard tests concurred, a near-perfect prediction of treatment success or failure emerged. The study involved extensive screening of over 500 antibiotic-bacteria combinations, with the findings indicating that the standard test is inaccurate approximately 15% of the time. Since doctors depend on this test to guide treatment decisions, it may result in the prescription of inappropriate antibiotics.

Medical professionals are aware of the gold-standard test's limitations. When the suggested antibiotics prove ineffective, physicians must draw upon their experience to determine the most suitable antibiotic(s) for their patients. This study offers a potential solution to bridge the gap between the antibiotics suggested by standard testing and actual patient outcomes. The new test could lead to substantial cost savings for the healthcare sector as they endeavor to identify novel drugs to combat antimicrobial-resistant infections.

“Reevaluation of FDA-approved antibiotics may be of far greater benefit than the time and cost of developing new drugs to combat antimicrobial resistance,” explained Santa Barbara Cottage Hospital physician Lynn Fitzgibbons, M.D., “potentially leading to significant life-savings and cost-savings.”

Related Links:
UC Santa Barbara 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more